A Comprehensive Analysis of Extraction Methods, Phytochemical Characterization and Neuroprotective Potential of Curcumin
4 affiliations
- 1Pharmacology Laboratory, Institute of Research for Food Safety and Health (IRC-FSH), Department of Health Sciences, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, Italy
- 2Laboratory of Mass Spectrometry and Proteomics, Department of Experimental and Clinical Medicine, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, Italy
- 3Veterinary Pharmacology Laboratory, Institute of Research for Food Safety and Health (IRC-FSH), Department of Health Sciences, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, Italy
- 4Renato Dulbecco Institute, 88046 Lamezia Terme, Italy
Abstract
Curcumin, a natural polyphenol derived from Curcuma longa, exhibits multi-targeted anti-inflammatory, antioxidant, and neuroprotective activities. This review aims to evaluate its extraction methodologies, synthetic pathways, and neuroprotective potential across preclinical and clinical paradigms, while addressing bioavailability barriers and commercial adulteration. In cellular models (BV-2, U87), curcumin inhibits TLR4/MyD88/NF-κB and NLRP3 inflammasome signaling, resulting in the downregulation of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) and enzymes (COX-2, iNOS), while simultaneously activating Nrf2/ARE antioxidant pathways. Moreover, it facilitates the polarization of neuroprotective M2 microglia. In animal models of ischemic stroke, traumatic brain injury, and Parkinson’s disease, curcumin reduces neuroinflammation, protects dopaminergic neurons, and maintains the integrity of the blood–brain barrier. Advanced nanocarriers such as PLGA nanoparticles, exosomes, and lipid complexes bypass rapid hepatic metabolism, thereby increasing brain bioavailability. Clinical data demonstrate that bioavailable formulations (Theracurmin, Longvida, CurQfen) could improve memory function and reduce cerebral amyloid and tau deposits in subjects without dementia and with mild cognitive impairment. Conversely, the use of unformulated curcumin results in inconsistent findings in trials for Alzheimer’s and Parkinson’s diseases owing to its poor systemic absorption. In conclusion, Curcumin might represent a promising multitarget neuroprotective agent; however, addressing pharmacokinetic limitations via bioavailable delivery systems and implementing rigorous quality control to prevent commercial adulteration are essential for effective clinical application.
Related
- Extraction Optimization and Preliminary Neuroprotective Evaluation of Asiaticoside and Asiatic Acid from Centella asiatica (L.) Urb Using In Vitro and In Silico Approaches
- Dexmedetomidine as a potential neuroprotective agent against Alzheimer’s disease: molecular mechanisms and therapeutic perspectives
- Neuroprotective Potential of the Edible Seaweed Pterocladiella capillacea: Bioactivity Coupled LC-MS/MS, Metabolomics Annotation, Validation, and Network Pharmacology
- Neuroprotective Effects of Carica papaya in Experimental Models of Neurodegeneration: A Comprehensive Review.
- Phytochemical study, solvent extraction efficiency, and antioxidant and antibacterial activities of Moroccan Teucrium polium L. ssp. thymoïdes: a combined experimental and DFT study
BibTeX
@article{dardano2026comprehensive,
title = {{A Comprehensive Analysis of Extraction Methods, Phytochemical Characterization and Neuroprotective Potential of Curcumin}},
author = {Denise Maria Dardano and Roberta Macrì and Maria Serra and Carmen Altomare and Giovanna Ritorto and Sara Ussia and Muhammad Mubeen Jamal Anwar and Ernesto Palma and Vincenzo Mollace},
journal = {Nutrients},
year = {2026},
month = oct,
doi = {10.3390/nu18203343},
url = {https://www.mdpi.com/2072-6643/18/20/3343},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - A Comprehensive Analysis of Extraction Methods, Phytochemical Characterization and Neuroprotective Potential of Curcumin
AU - Denise Maria Dardano
AU - Roberta Macrì
AU - Maria Serra
AU - Carmen Altomare
AU - Giovanna Ritorto
AU - Sara Ussia
AU - Muhammad Mubeen Jamal Anwar
AU - Ernesto Palma
AU - Vincenzo Mollace
PY - 2026
DA - 2026/10/01
JO - Nutrients
DO - 10.3390/nu18203343
UR - https://www.mdpi.com/2072-6643/18/20/3343
AB - Curcumin, a natural polyphenol derived from Curcuma longa, exhibits multi-targeted anti-inflammatory, antioxidant, and neuroprotective activities. This review aims to evaluate its extraction methodologies, synthetic pathways, and neuroprotective potential across preclinical and clinical paradigms, while addressing bioavailability barriers and commercial adulteration. In cellular models (BV-2, U87), curcumin inhibits TLR4/MyD88/NF-κB and NLRP3 inflammasome signaling, resulting in the downregulation of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) and enzymes (COX-2, iNOS), while simultaneously activating Nrf2/ARE antioxidant pathways. Moreover, it facilitates the polarization of neuroprotective M2 microglia. In animal models of ischemic stroke, traumatic brain injury, and Parkinson’s disease, curcumin reduces neuroinflammation, protects dopaminergic neurons, and maintains the integrity of the blood–brain barrier. Advanced nanocarriers such as PLGA nanoparticles, exosomes, and lipid complexes bypass rapid hepatic metabolism, thereby increasing brain bioavailability. Clinical data demonstrate that bioavailable formulations (Theracurmin, Longvida, CurQfen) could improve memory function and reduce cerebral amyloid and tau deposits in subjects without dementia and with mild cognitive impairment. Conversely, the use of unformulated curcumin results in inconsistent findings in trials for Alzheimer’s and Parkinson’s diseases owing to its poor systemic absorption. In conclusion, Curcumin might represent a promising multitarget neuroprotective agent; however, addressing pharmacokinetic limitations via bioavailable delivery systems and implementing rigorous quality control to prevent commercial adulteration are essential for effective clinical application.
SN - 2072-6643
ER -